LENZ (LENZ Therapeutics) ROE % Adjusted to Book Value: -53.91% (As of Mar. 2026)


LENZ LENZ Therapeutics Inc LENZ
12 GF Score
Price $5.75
! 2 Warning Signs
View Full Analysis

What is LENZ Therapeutics ROE % Adjusted to Book Value?

LENZ Therapeutics LENZ -1.03% 12 ROE % Adjusted to Book Value is -53.91% as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

LENZ Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -62.53%. LENZ Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 1.16. LENZ Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -53.91%.

LENZ Therapeutics ROE % Adjusted to Book Value Related Terms

LENZ Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for LENZ Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LENZ Therapeutics ROE % Adjusted to Book Value Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -22.97 -19.11

LENZ Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.00 -7.40 -4.86 -34.11 -53.91

LENZ vs KRRO, ANTX, OKUR: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, LENZ Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LENZ Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where LENZ Therapeutics's ROE % Adjusted to Book Value falls into.


LENZ
12GF Score
LENZ Therapeutics Inc LENZ
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LENZ Therapeutics ROE % Adjusted to Book Value Calculation

LENZ Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-33.63% / 1.76
=-19.11%

LENZ Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-62.53% / 1.16
=-53.91%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -53.91% mean?
LENZ Therapeutics (LENZ) has a ROE % Adjusted to Book Value of -53.91% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on LENZ Therapeutics and its competitors.
Is LENZ Therapeutics' ROE % Adjusted to Book Value too high?
LENZ Therapeutics' current ROE % Adjusted to Book Value is -53.91%. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' ROE % Adjusted to Book Value compare to KRRO and ANTX?
LENZ Therapeutics' ROE % Adjusted to Book Value of -53.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on LENZ Therapeutics and its competitors. LENZ Therapeutics's current ROE % Adjusted to Book Value is -53.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current ROE % Adjusted to Book Value of -53.91%. The current ROE % Adjusted to Book Value is -53.91%. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current ROE % Adjusted to Book Value is -53.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LENZ Therapeutics Business Description

Address 201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA, USA, 92075
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score

Get the complete analysis for LENZ

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.75
Price